For the Inventor, By the Inventor

Enter assignee name

Utrecht, Netherlands

Merus N.v.

USPTO Granted Patents = 42

CIPO Patents = 3

EPO Patents = 18

Trademarks = 11

Forward Citations = 135

Loading Chart...

Loading Chart...

35 inventors (with patents filed for the assignee):

Ton Logtenberg (35 out of 56 patents)

Mark Throsby (20 out of 46 patents)

Cornelis Adriaan De Kruif (18 out of 49 patents)

4. Rui Daniel Pinto (9 out of 9 patents)

5. Erwin Houtzager (9 out of 12 patents)

6. Alexander Berthold Hendrik Bakker (8 out of 16 patents)

7. Linda Johanna Aleida Hendriks (7 out of 10 patents)

8. Pieter Fokko Van Loo (7 out of 10 patents)

9. Cecilia Anna Wilhelmina Geuijen (7 out of 12 patents)

10. Robert Arjen Kramer (7 out of 15 patents)

11. John De Kruif (3 out of 3 patents)

12. Rinse Klooster (3 out of 7 patents)

13. Paulus Johannes Tacken (3 out of 4 patents)

14. Ronald Hendrik Brus (2 out of 3 patents)

15. Robertus Cornelis Roovers (2 out of 5 patents)

Core Competencies:

CD3 Binding Molecules

Bispecific Antibodies

ErbB-2 Antibodies

ErbB-3 Antibodies

T Cell Engagers

Cancer Treatment

Binding Molecules

PD-1 Binding Domains

Multivalent Antibodies

Antibody Production

EGFR Binding Antibodies

Non-Human Antibody Models

42 patents: Sort by Forward Citations

1. 12460002 - CD3 binding molecules (2025-11-04),

2. 12291798 - Generation of binding molecules (2025-05-06),

3. 12247078 - ERBB-2 and ERBB-3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene (2025-03-11),

4. 12195551 - Combination of an ErbB-2/ErbB-3 bispecific antibody with endocrine therapy for breast cancer (2025-01-14),

5. 12139548 - Antibody that binds ErbB-2 and ErbB-3 (2024-11-12),

6. 12123043 - Methods and means for the production of Ig-like molecules (2024-10-22),

7. 12060418 - Bispecific IgG antibodies as T cell engagers (2024-08-13),

8. 11993654 - PD-1 binding domains (2024-05-28),

9. 11952424 - Multivalent antibody (2024-04-09),

10. 11939394 - Binding molecules that inhibit cancer growth (2024-03-26),

11. 11926859 - Methods and means for the production of Ig-like molecules (2024-03-12),

12. 11925174 - Antibody producing non-human animals (2024-03-12),

13. 11873338 - CLEC12AxCD3 bispecific antibodies and methods for the treatment of disease (2024-01-16),

14. 11820825 - Methods of treating a subject having an EGFR-positive and/or ErbB-3-positive tumor (2023-11-21),

15. 11785924 - Antibody producing non-human animals (2023-10-17),

Merus N.V. is a clinical-stage immuno-oncology company focused on developing innovative bispecific antibody therapies to treat cancer. The company's proprietary technology, called Biclonics®, allows for the design and development of bispecific antibodies that can simultaneously target and bind to two different epitopes, enhancing their therapeutic potential. Merus is committed to advancing its pipeline of novel therapeutic candidates to address unmet medical needs and improve the lives of patients with cancer.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

42 Patents

#5 in Utrecht

#197 in Netherlands

#15,864 in the World

Utrecht, Netherlands

Merus N.v.

Forward Citations = 135

35 inventors:

Ton Logtenberg (35 out of 56 patents)

Mark Throsby (20 out of 46 patents)

Cornelis Adriaan De Kruif (18 out of 49 patents)

4. Rui Daniel Pinto (9 out of 9 patents)

5. Erwin Houtzager (9 out of 12 patents)

Please report any incorrect information to support@idiyas.com

Loading…